Exact Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating

Exact Sciences sees its Relative Strength Rating enter the elite 90-plus level. The post Exact Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating appeared first on Investor's Business Daily.

Continue Reading Exact Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating

Stock Upgrades: Editas Medicine Shows Rising Relative Strength

Editas Medicine sees its Relative Strength Rating enter the 80-plus level. The post Stock Upgrades: Editas Medicine Shows Rising Relative Strength appeared first on Investor's Business Daily.

Continue Reading Stock Upgrades: Editas Medicine Shows Rising Relative Strength

Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating

Atara Biotherapeutics sees its Relative Strength Rating enter the 80-plus level. The post Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Continue Reading Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating

Zymeworks Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Zymeworks shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83. The post Zymeworks Earns Relative Strength Rating Upgrade; Hits Key Benchmark appeared first on Investor's Business Daily.

Continue Reading Zymeworks Earns Relative Strength Rating Upgrade; Hits Key Benchmark

PTC Therapeutics Sees IBD RS Rating Climb To 74

A Relative Strength Rating upgrade for PTC Therapeutics shows improving technical performance. Will it continue? The post PTC Therapeutics Sees IBD RS Rating Climb To 74 appeared first on Investor's Business Daily.

Continue Reading PTC Therapeutics Sees IBD RS Rating Climb To 74

Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure

Eli Lilly inked a deal to sell up to 650,000 vials of its Covid-19 treatment candidate to the U.S., though the drug has failed a test in treating hospitalized patients. LLY stock slipped. The post Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure appeared first on Investor's Business Daily.

Continue Reading Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure

Ultragenyx Pharmaceutical Sales More Than Triple, Pares Losses

Ultragenyx Pharmaceutical posted third-quarter results late Tuesday that beat views on the top and bottom lines after RARE stock hit a nearly five-year high, revenue more than triples. The post Ultragenyx Pharmaceutical Sales More Than Triple, Pares Losses appeared first on Investor's Business Daily.

Continue Reading Ultragenyx Pharmaceutical Sales More Than Triple, Pares Losses

Dow Jones Slips, Nasdaq Rises After Monday's Market Rout; Microsoft Earnings Ahead

Stocks were mixed midday Tuesday, after Monday's big sell-off. The Dow Jones Industrial Average reversed lower after an early gain. The post Dow Jones Slips, Nasdaq Rises After Monday's Market Rout; Microsoft Earnings Ahead appeared first on Investor's Business Daily.

Continue Reading Dow Jones Slips, Nasdaq Rises After Monday's Market Rout; Microsoft Earnings Ahead

Biotechs, Payment, E-Commerce Leaders To Report: Investing Action Plan

 Amgen and Gilead report as they also develop Covid-19 drugs, while Visa and Mastercard are also due. The post Biotechs, Payment, E-Commerce Leaders To Report: Investing Action Plan appeared first on Investor's Business Daily.

Continue Reading Biotechs, Payment, E-Commerce Leaders To Report: Investing Action Plan

Stocks Showing Rising Market Leadership: Sangamo Therapeutics Earns 83 RS Rating

A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. The post Stocks Showing Rising Market Leadership: Sangamo Therapeutics Earns 83 RS Rating appeared first on Investor's Business Daily.

Continue Reading Stocks Showing Rising Market Leadership: Sangamo Therapeutics Earns 83 RS Rating

Moderna Vaccine Gets U.K. “Rolling Review”; Novavax Expands Trials

Moderna and Novavax announced advances for their respective Covid-19 vaccine candidates, with the U.K. starting a 'rolling review' of Moderna's vaccine and Novavax expanding its key trials. The post Moderna Vaccine Gets U.K. "Rolling Review"; Novavax Expands Trials appeared first on Investor's Business Daily.

Continue Reading Moderna Vaccine Gets U.K. “Rolling Review”; Novavax Expands Trials

Pfizer Earnings Mixed; Drug Giant Steady

Pfizer earnings narrowly beat third-quarter views but revenue came in short. PFE stock was little changed before Tuesday's open. The post Pfizer Earnings Mixed; Drug Giant Steady appeared first on Investor's Business Daily.

Continue Reading Pfizer Earnings Mixed; Drug Giant Steady

LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials

Eli Lilly early Tuesday posted third-quarter earnings and sales that missed Wall Street expectations and said that one of its Covid-19 treatments failed in clinical trials; LLY stock fell. The post LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials appeared first on Investor's Business Daily.

Continue Reading LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials

Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance

Merck early Tuesday reported better-than-expected third-quarter earnings and sales and slightly raised its guidance. The post Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance appeared first on Investor's Business Daily.

Continue Reading Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance

Novartis Earnings Top, Sales Miss; NVS Stock Falls

Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant. Shares fell. The post Novartis Earnings Top, Sales Miss; NVS Stock Falls appeared first on Investor's Business Daily.

Continue Reading Novartis Earnings Top, Sales Miss; NVS Stock Falls

Microsoft, AMD Earnings To Rise: Investing Action Plan

Advanced Micro Devices leads a packed week of more chip earnings, while Microsoft begins a busy week for the top tech stocks. The post Microsoft, AMD Earnings To Rise: Investing Action Plan appeared first on Investor's Business Daily.

Continue Reading Microsoft, AMD Earnings To Rise: Investing Action Plan

Tiny Mirati Therapeutics Gets Jump On Giant Amgen In Cancer Drug

Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The post Tiny Mirati Therapeutics Gets Jump On Giant Amgen In Cancer Drug appeared first on Investor's Business Daily.

Continue Reading Tiny Mirati Therapeutics Gets Jump On Giant Amgen In Cancer Drug

Dow Dives 700 Points In Stock Market Rout; Coronavirus Cases Spike, No Deal In Sight

A stock sell-off turned into a rout midday Monday, with the Dow Jones Industrial Average diving 700 points as coronavirus cases spike in the U.S. and Europe. The post Dow Dives 700 Points In Stock Market Rout; Coronavirus Cases Spike, No Deal In Sight appeared first on Investor's Business Daily.

Continue Reading Dow Dives 700 Points In Stock Market Rout; Coronavirus Cases Spike, No Deal In Sight

Stocks With Rising Relative Price Strength: Revance Therapeutics

A Relative Strength Rating upgrade for Revance Therapeutics shows improving technical performance. The post Stocks With Rising Relative Price Strength: Revance Therapeutics appeared first on Investor's Business Daily.

Continue Reading Stocks With Rising Relative Price Strength: Revance Therapeutics

Stocks To Watch: Exact Sciences Sees RS Rating Rise To 81

Exact Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. The post Stocks To Watch: Exact Sciences Sees RS Rating Rise To 81 appeared first on Investor's Business Daily.

Continue Reading Stocks To Watch: Exact Sciences Sees RS Rating Rise To 81

Covid Roundup: AstraZeneca's Positive Vaccine Data; Moderna's New Deal

AstraZeneca posted positive interim Phase 2 testing data on its Covid-19 vaccine candidate in older adults, while Moderna inked a supply contract with Qatar, as MRNA stock, AZN stock rose. The post Covid Roundup: AstraZeneca's Positive Vaccine Data; Moderna's New Deal appeared first on Investor's Business Daily.

Continue Reading Covid Roundup: AstraZeneca's Positive Vaccine Data; Moderna's New Deal

Best ESG Companies By Category: These Are The Top 3 ESG Stocks In 8 Industries

What are the best ESG companies that lead their industry? We list the three high-ranking ESG stocks with the highest growth stock ratings in their business. The post Best ESG Companies By Category: These Are The Top 3 ESG Stocks In 8 Industries appeared first on Investor's Business Daily.

Continue Reading Best ESG Companies By Category: These Are The Top 3 ESG Stocks In 8 Industries

Top Tech Stocks To Take Over Earnings Season: Investing Action Plan

Big tech stocks like Apple, Amazon, Microsoft, Alphabet and Facebook will take the spotlight during the next phase of earnings season. The post Top Tech Stocks To Take Over Earnings Season: Investing Action Plan appeared first on Investor's Business Daily.

Continue Reading Top Tech Stocks To Take Over Earnings Season: Investing Action Plan

Stock Market Rally Keeps Pulling Back; Tesla, GM, Snap, Intel, PayPal In Focus: Weekly Review

The stock market rally retreated this week with the major indexes testing key levels and many growth stocks hit. Intel, Snap, Tesla earnings were notable. The post Stock Market Rally Keeps Pulling Back; Tesla, GM, Snap, Intel, PayPal In Focus: Weekly Review appeared first on Investor's Business Daily.

Continue Reading Stock Market Rally Keeps Pulling Back; Tesla, GM, Snap, Intel, PayPal In Focus: Weekly Review

Stocks Showing Improved Relative Strength: Exact Sciences

Exact Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post Stocks Showing Improved Relative Strength: Exact Sciences appeared first on Investor's Business Daily.

Continue Reading Stocks Showing Improved Relative Strength: Exact Sciences

Editas Medicine Scores Relative Strength Rating Upgrade; Hits Key Benchmark

Editas Medicine sees its Relative Strength Rating move into the 80-plus level. The post Editas Medicine Scores Relative Strength Rating Upgrade; Hits Key Benchmark appeared first on Investor's Business Daily.

Continue Reading Editas Medicine Scores Relative Strength Rating Upgrade; Hits Key Benchmark

Sangamo Therapeutics Earns Technical Rating Upgrade

Sangamo Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Sangamo Therapeutics Earns Technical Rating Upgrade appeared first on Investor's Business Daily.

Continue Reading Sangamo Therapeutics Earns Technical Rating Upgrade

Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?

Bristol Myers stock has slipped this year. But acquiring Celgene has bolstered the pharmaceutical company's sales, and the pending acquisition of MyoKardia might also. So is BMY stock a buy? The post Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy? appeared first on Investor's Business Daily.

Continue Reading Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?

Dow Jones Today, Futures Rise, Europe Rallies As Coronavirus Stimulus Talks Lag, Intel Tumbles

Gilead Sciences jumped on an FDA approval, Mattel soared on earnings and disappointing earnings from Intel dragged on the Dow Jones Today. The post Dow Jones Today, Futures Rise, Europe Rallies As Coronavirus Stimulus Talks Lag, Intel Tumbles appeared first on Investor's Business Daily.

Continue Reading Dow Jones Today, Futures Rise, Europe Rallies As Coronavirus Stimulus Talks Lag, Intel Tumbles

Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir

Gilead Sciences got FDA approval for its Covid-19 treatment that already had emergency authorization, remdesivir, sending GILD stock up after hours on the day shares touched a seven-year low. The post Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir appeared first on Investor's Business Daily.

Continue Reading Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir

Moderna Covid-19 Vaccine Nears; Passes Key Milestone In Final Testing

Moderna said it's completed the enrollment of 30,000 participants in the final-phase testing of its Covid-19 vaccine candidate, putting it on track for possible approval this year; MRNA rose. The post Moderna Covid-19 Vaccine Nears; Passes Key Milestone In Final Testing appeared first on Investor's Business Daily.

Continue Reading Moderna Covid-19 Vaccine Nears; Passes Key Milestone In Final Testing

Stocks With Rising Relative Strength: Sarepta Therapeutics

Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Stocks With Rising Relative Strength: Sarepta Therapeutics appeared first on Investor's Business Daily.

Continue Reading Stocks With Rising Relative Strength: Sarepta Therapeutics

Top-Rated Stocks Near Buy Point Ahead Of Earnings: Regeneron Pharmaceutical

Regeneron Pharmaceutical is near a buy zone with earnings due on or around Nov. 5. The post Top-Rated Stocks Near Buy Point Ahead Of Earnings: Regeneron Pharmaceutical appeared first on Investor's Business Daily.

Continue Reading Top-Rated Stocks Near Buy Point Ahead Of Earnings: Regeneron Pharmaceutical

U.S. Health Officials Optimistic One Or Two Covid-19 Vaccines Ready This Year

The leaders of key U.S. health agencies said in a media briefing Wednesday they are optimistic one or two Covid-19 vaccines will be approved and begin distribution later this year. The post U.S. Health Officials Optimistic One Or Two Covid-19 Vaccines Ready This Year appeared first on Investor's Business Daily.

Continue Reading U.S. Health Officials Optimistic One Or Two Covid-19 Vaccines Ready This Year

Arrowhead Pharma Shows Market Leadership With Jump To 83 RS Rating

Arrowhead Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 83. The post Arrowhead Pharma Shows Market Leadership With Jump To 83 RS Rating appeared first on Investor's Business Daily.

Continue Reading Arrowhead Pharma Shows Market Leadership With Jump To 83 RS Rating

Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial

Crispr Therapeutics said a patient in a Phase 1 clinical trial of a CAR-T therapy to treat a type of B-cell lymphoma died 52 days after infusion, sending CRSP stock plunging early Wednesday. The post Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial appeared first on Investor's Business Daily.

Continue Reading Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial

Biogen Earnings Beat, But Full-Year Guidance Cut

Biogen earnings and sales fell less than expected in the third quarter, but the biotech giant cut full-year guidance. BIIB stock was little changed. The post Biogen Earnings Beat, But Full-Year Guidance Cut appeared first on Investor's Business Daily.

Continue Reading Biogen Earnings Beat, But Full-Year Guidance Cut

Thermo Fisher Earnings Growth Is Best In Years, Crushing Views

Thermo Fisher earnings rose 91% vs. a year earlier, the best in years. The life sciences giant also easily beat sales views. TMO stock edged up, near highs. The post Thermo Fisher Earnings Growth Is Best In Years, Crushing Views appeared first on Investor's Business Daily.

Continue Reading Thermo Fisher Earnings Growth Is Best In Years, Crushing Views

Merck Posts Positive Data For Pneumococcal Vaccine Candidate, Eyes Approval

Merck posted positive Phase 3 clinical trials results for a pneumococcal vaccine candidate and said it remains on track to apply for U.S. FDA approval this year. MRK stock edged higher. The post Merck Posts Positive Data For Pneumococcal Vaccine Candidate, Eyes Approval appeared first on Investor's Business Daily.

Continue Reading Merck Posts Positive Data For Pneumococcal Vaccine Candidate, Eyes Approval

Gilead Coronavirus Drug Treated President — But Is GILD Stock A Buy?

Biotech company Gilead early on gained the Food And Drug Administration's nod for its coronavirus treatment, but new study results on remdesivir's effectiveness conflict. Is GILD stock a buy? The post Gilead Coronavirus Drug Treated President — But Is GILD Stock A Buy? appeared first on Investor's Business Daily.

Continue Reading Gilead Coronavirus Drug Treated President — But Is GILD Stock A Buy?